OUR TEAM MEMBERS
Chris Buyse was CFO at ThromboGenics NV from September 2006 until June 2014. He has 30 years of experience in international company finance and in running and establishing best financial practice. He was previously CFO of the Belgian biotechnology company CropDesign. Before this, he was Finance Director of WorldCom/MCI Belux, and was CFO and interim CEO of Keyware Technologies, in addition, he held several financial positions at Suez Lyonnaise des Eaux and Unilever. He is currently serving as an independent Board Member of a few companies, mostly active in life sciences such as Celyad, Iteos and Bioxodes.
Philippe Monteyne holds an M.D. degree trained as a Neurologist and a Ph.D. in Viral Immunology, both at the UCL (Univ. Cathol. de Louvain), followed by a post-doctoral fellowship at Pasteur Institute, Paris. During the last 20 years, he held senior positions in top pharma companies such as SmithKline Beecham, GSK Biologicals (as Head of Global Vaccine Development) and GSK Rare Diseases (Head of Development and Chief Medical Officer) and SANOFI (Vice President R&D France). He is also currently member of different Strategic Advisory Committees. He is also visiting Professor of Neurology at the UCL.
Jan Van den Bossche
Jan Van den Bossche holds a Master Degree in Applied Economic Sciences at the KU Leuven. He worked for more than 12 years as a biotech analyst at Petercam. He was involved in numerous public and private transactions of Belgian and Dutch Biotech companies, such as ThromboGenics, Tigenix, UCB, AMT (Uniqure), IBA, MDxHealth . Before he joined Fund+, he was for more than 2 years part of the investor relations team at the Dutch life sciences and materials sciences company DSM (Geleen, NL).
Alexandra Tolia holds a Ph.D. in Medical Sciences from the KU Leuven, followed by a postdoctoral fellowship at UCSF, and an executive degree in General Management from the Solvay Brussels School of Economics and Management. Before joining Fund+, Alexandra led investments in private and public companies at PMV and Hunza Ventures, where she built strong Life sciences portfolios in Europe and the US. Alexandra is the author of high impact publications in the fields of neurodegeneration and cardiovascular disease and has served as board member in several companies active in biotech, diagnostics and medical technologies.
Louis Declerck is an MD and Biomedical Engineer, trained at the KU Leuven and Ghent University with a specific interest in Biotechnology & Bio-electronics, Neuro-engineering and emerging Medical devices. After one year of co-residency in Neurosurgery, Louis decided to start Biomedical Engineering at Ghent University to explore and contribute to new businesses in the Biomedical and Biotechnology industry. Louis joined Fund+ as Investment Analyst shortly after a one year fellowship in Fund+ during his graduation year. Recently, Louis has been appointed as Associate.
Sarah Van De Sype
Sarah joined the Fund+ team in November 2018 as an Administrative Assistant. She is an experienced Management and Executive assistant, previously working for PwC, ThromboGenics and KU Leuven.
Diane De Wyngaert
Diane holds a bachelor degree in informatics. She joined Life Sciences Research Partners in 2007 as administrative assistant, where she still is in charge of the Administration, Human Resources and Bookkeeping. Diane joined Fund+ from the start-up.